Project Grant R21AG093265
Award Date
5/15/25
Completion Date
4/30/27
Dollars Obligated
$461K
Federal Agency
National Institute on Aging
Awardee
Yale Univ (FL6GV84CKN57)
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Connecticut, USA
Similar Awards
The University of Pittsburgh has been awarded a $325,950 project grant from the National Institute on Aging's Aging Research program (CFDA 93.866) to conduct research on preventing pulmonary fibrosis. The research aims to establish that the tyrosine kinase protein FGR, which is induced in senescent lung cells, initiates pulmonary fibrosis by secreting proinflammatory proteins and recruiting inflammatory cells. The project will use mouse models to confirm the role of FGR in pulmonary fibrosis and...
This $162,540 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to elucidate the mechanism by which aging exacerbates defects in cell quality control and metabolism, disrupting alveolar epithelial type II (AT2) progenitor cell function and enhancing aberrant transitional cell accumulation in pulmonary fibrosis. The research will utilize an aged murine model of idiopathic pulmonary...
This $774,585 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports research to investigate the role of inflammatory fibroblasts in pulmonary fibrosis. The key objectives are to: Determine the mechanisms driving the emergence of inflammatory fibroblasts from normal alveolar fibroblasts and how these cells modulate inflammatory responses and fibrosis in different lung injury models....
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $683,564 to The Trustees of the University of Pennsylvania to conduct research on alveolar epithelial stress signaling in lung fibrosis. The key objectives are to: 1) determine how aberrant transitional epithelial cells contribute to fibrosis and activate alveolar fibroblasts; and 2) define how PERK-ISR signaling impacts epithelial differentiation and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $545,400 to Georgia Tech Research Corp to elucidate the contributions of FAK mechanosensing to extracellular matrix (ECM) remodeling, senescence, apoptosis-resistance, and the senescence-associated secretory pathway (SASP) in pulmonary fibrosis. The key objectives are to engineer 3D microtissue models using human...
This $651,019 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to elucidate the mediators and pathways that contribute to dysfunctional epithelial repair in pulmonary fibrosis. The grant, awarded to the Regents of the University of Michigan, aims to: 1) identify factors driving dysfunctional epithelial states in persistent lung fibrosis, 2) determine the impact of...
This $787,266 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) supports research to investigate the role of basal-like cells and WNT7A signaling in idiopathic pulmonary fibrosis (IPF). The goal is to test the hypothesis that dysregulated signaling pathways in pathologically accumulated basal-like cells in IPF lungs promote fibrosis by activating WNT signaling, leading to impaired renewal of type 2...
The Project Grant award R01HL169611, "INTRACELLULAR COLLAGEN SENSING IN PULMONARY FIBROSIS", is funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The $595,286 award supports research to delineate pathways regulating collagen clearance and identify mechanisms underlying the impaired collagen turnover observed in idiopathic pulmonary fibrosis (IPF). The research will utilize mouse models, human lung...
This $1,193,262 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to advance a novel adeno-associated virus (AAV)-mediated gene therapy for the treatment of idiopathic pulmonary fibrosis (IPF). The research team at the University of California, San Francisco (UCSF) will rigorously validate the efficacy of the AAV-SGPL1 gene therapy in IPF mouse models and lung tissue samples. Specifically, they...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant totaling $299,295 to Fibrobiologics LLC to support the preclinical development of a novel therapeutic agent for the treatment of idiopathic pulmonary fibrosis (IPF). The funding, provided through the Cardiovascular Diseases Research program (CFDA 93.837), will enable Fibrobiologics to determine the antifibrotic activity of the peptide M10 in primary lung fibroblasts from IPF patients and evaluate its efficacy in two...